JOHN VIERLING to Pyrrolidines
This is a "connection" page, showing publications JOHN VIERLING has written about Pyrrolidines.
Connection Strength
0.216
-
Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. N Engl J Med. 2018 01 25; 378(4):354-369.
Score: 0.035
-
Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials. Lancet Gastroenterol Hepatol. 2017 11; 2(11):814-823.
Score: 0.034
-
Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection. Ann Hepatol. 2016 Nov-Dec 2016; 15(6):834-845.
Score: 0.032
-
Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology. 2016 May; 63(5):1493-505.
Score: 0.031
-
Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. JAMA. 2015 May 05; 313(17):1736-44.
Score: 0.029
-
Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders. J Hepatol. 2015 Jul; 63(1):30-7.
Score: 0.028
-
Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut. 2015 Jun; 64(6):948-56.
Score: 0.027